The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia

American Journal of Cardiology

Volumn 79, Issue 5 A, 1997, Pages 24-28

  Pitt, Bertram ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; OXYGEN RADICAL; RAMIPRIL; RENIN;

ANIMAL CELL; ANIMAL TISSUE; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0030967623     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00126-4     Document Type: Conference Paper

References (37)

1. Lüscher TF. Endothelial dysfunction in atherosclerosis. J Myocard Ischemia 1995;7(suppl 1):15-20.
2. Yang X, Cai B, Sciacca RR, Cannon PJ. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res 1994;74:318-328.
3. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-1253.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
7. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996;27:1048-1052.
8. Vane JR, Änggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
9. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332: 512-521.
10. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
11. Dinerman JL, Mehta JL. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol 1990;16:207-222.
12. Raij L. Hypertension, endothelium, and cardiovascular risk factors. Am J Med 1991;90(suppl 2A):2A-13S-2A-18S.
13. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(suppl 4):S1-S14.
14. Tsurumi Y, Nagashima H, Ichikawa K-I, Sumiyoshi T, Hosoda S. Influence of plasma lipoprotein(a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 1995;26:1242-1250.
15. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-2146.
16. Rosano GMC, Barrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-136.
17. Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation 1995;92:2683-2689.
18. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991;11:1821-1829.
19. Boulanger CM, Tanner FC, Béa M-L, Hahn AWA, Werner A, Lüscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992;70:1191-1197.
20. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996;16:97-105.
21. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-265.
22. Pepine CJ, Pitt B, Bertrand ME, Timmis A. Emerging role of ACE inhibitors in vascular protection. J Myocard Ischemia 1995;7(suppl 1):50-58.
23. Chobanian AV, Haudenschild CC, Nickersen C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
24. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
25. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J 1994;128:1328-1332.
26. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993;100:149-156.
27. Torp-Pedersen C, Køber L, Carlsen J, on behalf of the TRACE Study Group. Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation study. Am Heart J 1996;132:235-243.
28. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677.
29. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
30. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178.
31. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
32. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
33. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
34. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-2524.
35. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
36. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
37. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-1500.